According to the National Health and Medical Research Council – NHMRC clinical trials across Australia are in the following categories:
– treatment trials to test new treatments, new medicines or combinations of medicines; or other new therapies such as surgery, the use of new medical devices or new approaches to surgery
– diagnostic or screening trials to evaluate tests or procedures to diagnose and detect diseases or conditions
– prevention trials to test new ways to prevent disease including medicines, vaccines, vitamins, or changes to diet, lifestyle or behaviour
Clinical trials in Australia need to be efficiently administrated and resourced with qualified healthcare professionals as well as suitable patients.
Shanny Dyer, CEO ARCS Australia talks about a recent summit where the CRO (Contract Research Organization) community was asked on the current state of clinical trials in Australia. Commentary from:
– Tanya Symons, Director at T Symons Associates
– Daniela Caiazza, Director Clinical Operations ANZ, Novotech CRO
– Adam Stoneley, Research Operations Manager, Icon Cancer Centre
– Gabrielle McKee, Chief Operating Officer, CNS Clinical Network
– Joe Taouk, Senior Director Research and Development, IQVIA
#AustralianHealthJournal #ClinicalTrials
You Might also like
-
CASE STUDY: Evolution in the medical device supply chain
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
-
Clinical research integrates with GP and Pharmacist workflows to supplement practice revenue
Clinical trials are crucial to the development of evidence-based preventative medicines. In addition, participation in clinical trials can also provide patients with opportunities to access new treatments.
“Clinical trials are at the heart of medical advances which look into new ways to treat, prevent, or detect disease. Volunteers often do so to help contribute to advancing scientific research, knowing that they are participating in the hope of helping future generations,” said Charlotte Bradshaw, CEO and Founder to Evrima Technologies.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.